The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-institutional, single-arm, phase 2 study of durvalumab plus amrubicin in patients with relapsed extensive-stage small cell lung cancer (Aphrodite trial).
 
Yuka Kato
Consulting or Advisory Role - Daiichi Sankyo Co., Ltd.
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo Company; Janssen; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst)
 
Koichi Azuma
No Relationships to Disclose
 
Kakuhiro Yamaguchi
No Relationships to Disclose
 
Toshihide Yokoyama
No Relationships to Disclose
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Hisamitsu Pharmaceutical; Kyowa Kirin Co., Ltd; Lilly Japan; MSD; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Lilly
 
Kota Sakamoto
No Relationships to Disclose
 
Hideki Uno
No Relationships to Disclose
 
Michihiro Yoshida
Stock and Other Ownership Interests - Takeda
 
Kadoaki Ohashi
No Relationships to Disclose